marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
scPharmaceuticals Balance Sheet 2011-2024 | SCPH
Annual Balance Sheet scPharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-7.83 M | -33.7 M | -66.4 M | -71.4 M | -52.4 M | -79.8 M | -109 M | -39.3 M | -1.57 M | - | - | - | - |
Long Term Debt |
38.8 M | 36.8 M | 7.35 M | - | 18.9 M | 6.83 M | 9.1 M | - | - | - | - | - | - |
Long Term Debt Current |
176 K | 567 K | 476 K | 460 K | 407 K | 353 K | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 20.7 M | 8.34 M | 9.31 M | 73.1 M | 18.1 M | - | - | - | - |
Total Current Liabilities |
13.1 M | 7.42 M | 14.8 M | 9.32 M | 5.24 M | 6.67 M | - | - | - | - | - | - | - |
Total Liabilities |
57.3 M | 51.8 M | 22.6 M | 26.9 M | 25.9 M | 15 M | 14.3 M | 76.8 M | 20.1 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-281 M | -227 M | -190 M | - | -129 M | -96.5 M | -67 M | -43.2 M | -18.8 M | - | - | - | - |
Total Assets |
94.5 M | 124 M | 79 M | 109 M | 77.3 M | 93.8 M | 120 M | 39.8 M | 1.85 M | - | - | - | - |
Cash and Cash Equivalents |
46.8 M | 71.1 M | 74.3 M | 71.8 M | 72.6 M | 89.5 M | 118 M | - | - | - | - | - | - |
Book Value |
37.2 M | 72.4 M | 56.5 M | 82.2 M | 51.4 M | 78.7 M | 106 M | -37.1 M | -18.2 M | - | - | - | - |
Total Shareholders Equity |
37.2 M | 72.4 M | 56.5 M | 82.2 M | 51.4 M | 78.7 M | 106 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet scPharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
51.1 M | 40 M | 39.4 M | 38.8 M | 38.3 M | 37.7 M | 37.3 M | 36.8 M | 114 K | 2.46 M | 4.91 M | 7.35 M | 9.78 M | 12.2 M | 14.5 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 6.83 M | 6.83 M | 6.83 M | 6.83 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
94.4 M | 56.2 M | 53.9 M | 57.3 M | 57 M | 50.7 M | 51.6 M | 51.8 M | 17.3 M | 18.7 M | 19.5 M | 22.6 M | 24.4 M | 24.6 M | 24.8 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 15 M | 15 M | 15 M | 15 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-348 M | -313 M | -295 M | -281 M | -268 M | -252 M | -238 M | -227 M | -217 M | -207 M | -197 M | -190 M | -182 M | -176 M | -169 M | -162 M | -162 M | -162 M | -162 M | -129 M | -129 M | -129 M | -129 M | -96.5 M | -96.5 M | -96.5 M | -96.5 M | -67 M | -67 M | -67 M | -67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
125 M | 65.5 M | 78.5 M | 94.5 M | 106 M | 114 M | 127 M | 124 M | 48.4 M | 59.2 M | 68.9 M | 79 M | 87.5 M | 93.6 M | 100 M | 109 M | 109 M | 109 M | 109 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 93.8 M | 93.8 M | 93.8 M | 93.8 M | 122 M | 122 M | 122 M | 122 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
91.5 M | 38.5 M | 58.4 M | 46.8 M | 35 M | 71.4 M | 75.5 M | 71.1 M | 41.5 M | 41.4 M | 51.8 M | 74.3 M | 79.5 M | 75.2 M | 75.8 M | 72 M | 71.8 M | 71.8 M | 71.8 M | 72.6 M | 72.6 M | 72.6 M | 72.6 M | 89.5 M | 89.5 M | 89.5 M | 89.5 M | 118 M | 118 M | 118 M | 118 M | 39.3 M | - | - | - | 1.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
30.7 M | 9.25 M | 24.6 M | 37.2 M | 49.1 M | 63.4 M | 75.8 M | 72.4 M | 31.1 M | 40.5 M | 49.4 M | 56.5 M | 63.1 M | 69 M | 75.5 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | 106 M | 106 M | 106 M | 106 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
30.7 M | 9.25 M | 24.6 M | 37.2 M | 49.1 M | 63.4 M | 75.8 M | 72.4 M | 31.1 M | 40.5 M | 49.4 M | 56.5 M | 63.1 M | 69 M | 75.5 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | 106 M | 106 M | 106 M | 106 M | -37.1 M | - | - | - | -18.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency